Catalent and Abzena both recently announced substantial investments into new biologics facilities. Catalent is spending up to $160 million to build a new manufacturing facility near Oxford, UK. Catalent plans to equip the facility with “state-of-the-art capabilities for the development and manufacture of biologic therapies and vaccines, including mRNA, proteins…
